Browsing by Author "Quera, Rodrigo"

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Corrigendum: Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer (vol 10, 1394, 2019)
    (2019) Landskron, Glauben; De la Fuente Lopez, Marjorie; Dubois Camacho, Karen; Diaz Jimenez, David; Orellana Serradell, Octavio; Romero Vera, Diego Ignacio; Sepulveda García, Santiago Alfonso; Salazar, Christian; Parada Venegas, Daniela; Quera, Rodrigo; Simian, Daniela; Gonzalez, Maria Julieta; Lopez Kostner, Francisco; Kronberg, Udo; Abedrapo, Mario; Gallegos, Ivan; Contreras, Hector R.; Pena, Cristina; Diaz Araya, Guillermo; Roa Strauch, Juan Carlos Enrique; Hermoso, Marcela A.
  • No Thumbnail Available
    Item
    Herpetic Esophagitis and Eosinophilic Esophagitis: A Potential Association
    (2021) Quera, Rodrigo; Sassaki, Ligia Yukie; Nunez, Paulina; Contreras, Luis; Bay, Constanza; Flores, Lilian
    Objective: Rare coexistence of disease or pathology
  • Thumbnail Image
    Item
    Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients
    (ELSEVIER GMBH, 2012) Candia, Enzo; Diaz Jimenez, David; Langjahr, Patricia; Nunez, Lucia E.; de la Fuente, Marjorie; Farfan, Nancy; Lopez Kostner, Francisco; Abedrapo, Mario; Alvarez Lobos, Manuel; Pinedo, George; Beltran, Caroll J.; Gonzalez, Carlos; Gonzalez, Maria Julieta; Quera, Rodrigo; Hermoso, Marcela A.
    Toll-like receptor 2 (TLR2) is a type I pattern recognition receptor that has been shown to participate in intestinal homeostasis. Its increased expression in the lamina propria has been associated with the pathogenesis in inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Recently, soluble TLR2 (sTLR2) variants have been shown to counteract inflammatory responses driven by the cognate receptor. Despite the evident roles of TLR2 in intestinal immunity, no study has elucidated the production and cellular source of sTLR2 in IBD. Furthermore, an increase in the population of activated macrophages expressing TLR2 that infiltrates the intestine in IBD has been reported. We aimed first to assess the production of the sTLR2 by UC and CD organ culture biopsies and lamina propria mononuclear cells (LPMCs) as well as the levels of sTLR2 in serum, and then characterize the cell population from lamina propria producing the soluble protein.
  • No Thumbnail Available
    Item
    Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer
    (2019) Landskron, Glauben; De la Fuente Lopez, Marjorie; Dubois-Camacho, Karen; Diaz-Jimenez, David; Orellana-Serradell, Octavio; Romero, Diego; Sepulveda, Santiago A.; Salazar, Christian; Parada-Venegas, Daniela; Quera, Rodrigo; Simian, Daniela; Gonzalez, Maria-Julieta; Kronberg, Udo; Abedrapo, Mario; Gallegos, Ivan; Contreras, Hector R.; Pena, Cristina; Diaz-Araya, Guillermo; Carlos Roa, Juan; Hermoso, Marcela A.
    In colorectal cancer (CRC), cancer-associated fibroblasts (CAFs) are the most abundant component from the tumor microenvironment (TM). CAFs facilitate tumor progression by inducing angiogenesis, immune suppression and invasion, thus altering the organization/composition of the extracellular matrix (i.e., desmoplasia) and/or activating epithelial-mesenchymal transition (EMT). Soluble factors from the TM can also contribute to cell invasion through secretion of cytokines and recently, IL-33/ST2 pathway has gained huge interest as a protumor alarmin, promoting progression to metastasis by inducing changes in TM. Hence, we analyzed IL-33 and ST2 content in tumor and healthy tissue lysates and plasma from CRC patients. Tissue localization and distribution of these molecules was evaluated by immunohistochemistry (using localization reference markers a-smooth muscle actin or alpha-SMA and E-cadherin), and clinical/histopathological information was obtained from CRC patients. In vitro experiments were conducted in primary cultures of CAFs and normal fibroblasts (NFs) isolated from tumor and healthy tissue taken from CRC patients. Additionally, migration and proliferation analysis were performed in HT29 and HCT116 cell lines. It was found that IL-33 content increases in left-sided CRC patients with lymphatic metastasis, with localization in tumor epithelia associated with abundant desmoplasia. Although ST2 content showed similarities between tumor and healthy tissue, a decreased immunoreactivity was observed in left-sided tumor stroma, associated to metastasis related factors (advanced stages, abundant desmoplasia, and presence of tumor budding). A principal component analysis (including stromal and epithelial IL-33/ST2 and alpha-SMA immunoreactivity with extent of desmoplasia) allowed us to distinguish clusters of low, intermediate and abundant desmoplasia, with potential to develop a diagnostic signature with benefits for further therapeutic targets. IL-33 transcript levels from CAFs directly correlated with CRC cell line migration induced by CAFs conditioned media, with rhlL-33 inducing a mesenchymal phenotype in HT29 cells. These results indicate a role of IL-33/ST2 in tumor microenvironment, specifically in the interaction between CAFs and epithelial tumor cells, thus contributing to invasion and metastasis in left-sided CRC, most likely by activating desmoplasia.
  • No Thumbnail Available
    Item
    Rectal diffuse large B cell lymphoma appearing after immunosuppression for ulcerative colitis. Report of one case
    (SOC MEDICA SANTIAGO, 2017) Quera, Rodrigo; Flores, Lilian; Simian, Daniela; Kronberg, Udo; Teresa Vial, Maria; Ladron De Guevara, David; Jose Garcia Rodriguez, Maria
    Primary colorectal lymphoma is a rare form of presentation of gastrointestinal tract lymphomas. Inflammatory bowel disease and its treatment are risk factors for its development. We report a 47-year-old male patient with Ulcerative Colitis of two years of evolution, treated initially with azathioprine and later on with infliximab. Due to a relapse in symptoms after the second dose of infliximab, a new coloncoscopy was performed showing a rectal ulcerative lesion, corresponding to a large cell Non-Hodgkin's Lymphoma. The patient was successfully treated with RCHOP chemotherapy (Rituximab cyclophosphamide doxorubicin vincristine prednisone). He is currently in disease remission.
  • Thumbnail Image
    Item
    Soluble ST2: A new and promising activity marker in ulcerative colitis
    (BAISHIDENG PUBL GRP CO LTD, 2011) Diaz Jimenez, David; Nunez, Lucia E.; Beltran, Caroll J.; Candia, Enzo; Suazo, Cristobal; Alvarez Lobos, Manuel; Gonzalez, Maria Julieta; Hermoso, Marcela A.; Quera, Rodrigo
    AIM: To correlate circulating soluble ST2 (sST2) levels with the severity of ulcerative colitis (UC) and serum levels of pro-inflammatory cytokines, and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.
  • No Thumbnail Available
    Item
    The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer
    (2018) Fuente López , Marjorie de la; Landskron Ramos, Glauben Tamara; Parada, Daniela; Dubois Camacho, Karen; Simian, Daniela; Martinez, Jalilie Maripaz; Romero Vera, Diego Ignacio; Roa Strauch, Juan Carlos Enrique; Chahuán, Isidora; Gutiérrez, Rocío; Lopez K, Francisco; Álvarez, Karin; Kronberg, Udo; López, Sebastian; Sanguinett, Antonella; Moreno, Natalia; Abedrapo, Mario; González, María-Julieta; Quera, Rodrigo; Hermoso R., Marcela A.
    A complex network of chemokines can influence cancer progression with the recruitment and activation of hematopoietic cells, including macrophages to the supporting tumor stroma promoting carcinogenesis and metastasis. The aim of this study was to investigate the relation between tissue and plasma chemokine levels involved in macrophage recruitment with tumor-associated macrophage profile markers and clinicopathological features such as tumor–node–metastases stage, desmoplasia, tumor necrosis factor-α, and vascular endothelial growth factor plasma content. Plasma and tumor/healthy mucosa were obtained from Chilean patients undergoing colon cancer surgery. Chemokines were evaluated from tissue lysates (CCL2, CCL3, CCL4, CCL5, and CX3CL1) by Luminex. Statistical analysis was performed using Wilcoxon match-paired test (p < 0.05). Macrophage markers (CD68, CD163, and iNOS) were evaluated by immunohistochemistry samples derived from colorectal cancer patients. Correlation analysis between chemokines and macrophage markers and clinicopathological features were performed using Spearman’s test. Plasmatic levels of chemokines and inflammatory mediators’ vascular endothelial growth factor and tumor necrosis factor-α were evaluated by Luminex. Tumor levels of CCL2 (mean ± standard deviation = 530.1 ± 613.9 pg/mg), CCL3 (102.7 ± 106.0 pg/mg), and CCL4 (64.98 ± 48.09 pg/mg) were higher than those found in healthy tissue (182.1 ± 116.5, 26.79 ± 22.40, and 27.06 ± 23.69 pg/mg, respectively p < 0.05). The tumor characterization allowed us to identify a positive correlation between CCL4 and the pro-tumor macrophages marker CD163 (p = 0.0443), and a negative correlation of iNOS with desmoplastic reaction (p = 0.0467). Moreover, we identified that tumors with immature desmoplasia have a higher CD163 density compared to those with a mature/intermediated stromal tissue (p = 0.0288). Plasmatic CCL4 has shown a positive correlation with inflammatory mediators (tumor necrosis factor-α and vascular endothelial growth factor) that have previously been associated with poor prognosis in patients. In conclusion High expression of CCL4 in colon cancer could induce the infiltration of tumor-associated macrophages and specifically a pro-tumor macrophage profile (CD163+ cells). Moreover, plasmatic chemokines could be considered inflammatory mediators associated to CRC progression as well as tumor necrosis factor-α and vascular endothelial growth factor. These data reinforce the idea of chemokines as potential therapeutic targets or biomarker in CRC.